Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

The expiration date of the key patent for guselkumab?
Dabrafenib btd date 2023?
Prolia and osteonecrosis?
Albendazole side effects in humans?
Are there specific stretches to avoid while on lipitor?

Divalproex 500 mg er?

See the DrugPatentWatch profile for Divalproex

What is divalproex 500 mg ER used for?

Divalproex 500 mg ER is an extended-release form of divalproex (a valproate medicine). Divalproex products are commonly used to treat epilepsy/seizure disorders and to manage bipolar disorder (including manic episodes). Extended-release (ER) is designed to release the medicine more slowly over time than immediate-release options.

What does “ER” change vs other divalproex tablets?

“ER” means extended-release. Compared with immediate-release formulations, ER typically aims to:
- smooth out drug levels over the day, and
- reduce dosing frequency for many patients.
Exact effects on day-to-day symptoms depend on the patient, the condition being treated, and the prescribed dose schedule.

How is divalproex 500 mg ER usually taken?

Patients usually take ER doses as directed by a clinician, often once daily for ER strengths (specific directions can vary by product and indication). ER tablets should typically be swallowed whole; altering them can change how the medicine is released.

What side effects do patients ask about most?

Common concerns with divalproex/valproate products include tiredness (somnolence), dizziness, gastrointestinal upset, and tremor. Patients also ask about more serious risks that require prompt medical attention, including liver-related problems and pancreatitis, and about mood/behavior changes.

Who should be extra careful or avoid it?

Valproate medicines carry important safety considerations. Clinicians usually exercise extra caution (or avoid use) in people with significant liver disease, and in people who are pregnant or could become pregnant, because valproate is strongly associated with fetal risk. Patients should follow prescriber guidance closely and discuss contraception and pregnancy plans.

What should patients know about drug interactions?

Valproex/ER formulations can interact with other medicines that affect the brain (sedatives), liver enzymes, or seizure control. Common medication categories that require review include other antiepileptics and drugs that increase sedation. A pharmacist or prescriber can check a specific interaction list for an individual’s regimen.

Is there a generic option for divalproex 500 mg ER?

Divalproex is widely available as generic medication in many markets. If you’re trying to confirm whether a specific “divalproex 500 mg ER” brand exists, your pharmacy label (or the specific manufacturer/NDC) is the most reliable way to verify the exact product.

How do I confirm I’m getting the right product?

Check the label for:
- drug name: divalproex
- strength: 500 mg
- dosage form: ER (extended-release)
- manufacturer/NDC number
Because “divalproex 500 mg” could be immediate-release in some listings, the ER designation matters for dosing and release profile.

Sources: None provided in your prompt.



Other Questions About Divalproex :

What is divalproex sodium used for? Divalproex sodium paten? Divalproex prolonged release tablets? Divalproex sodium generic name? Divalproex sodium name brand? Divalproex vs valproic acid? Divalproex er vs dr?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The evaluated claim about boxed-warning hepatotoxicity risk in children under 2 years, associated prodromal symptoms, and monitoring with baseline and frequent liver function tests (especially first 6 months) is fully supported by the provided FDA label excerpts (Box Warning and Section 5.1).

Category Scores

Warnings
100
Excellent

Accurate Statements

Children under 2 years are at a considerably increased risk of fatal hepatotoxicity with divalproex sodium/valproic acid.
BOX WARNING (HEPATOTOXICITY): explicitly states children under age two are at a considerably increased risk of developing fatal hepatotoxicity.
Serious or fatal hepatotoxicity may be preceded by nonspecific symptoms (e.g., malaise, weakness, lethargy, facial edema, anorexia, vomiting).
BOX WARNING (HEPATOTOXICITY) and Section 5.1: lists nonspecific symptoms preceding serious or fatal hepatotoxicity.
Close monitoring is required, including liver function tests before therapy and at frequent intervals (especially during the first six months).
BOX WARNING (HEPATOTOXICITY) and Section 5.1: advises close monitoring and states liver function tests should be performed prior to therapy and at frequent intervals thereafter, especially during the first six months.
Incidents usually occur during the first six months of treatment.
BOX WARNING (HEPATOTOXICITY) and Section 5.1: states incidents usually occur during the first six months.

Unsupported Statements

Contradictions

Important Omissions

The claim does not mention the label’s additional specific risk-factor subgroups (e.g., multiple anticonvulsants, congenital metabolic disorders, severe seizure disorders with mental retardation, organic brain disease) or the 'use with extreme caution and as a sole agent' instruction for the under-2 group when using the extended-release product.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The evaluated claim accurately reflects labeled risk and monitoring guidance; no contradictions were identified. Minor omission concerns relate only to completeness of risk-factor detail, not to the central warning and monitoring schedule.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Missing some label-specific details within the warning context (additional risk-factor subgroups and the 'extreme caution/as sole agent' phrasing for under-2 with extended-release).

Suggested Improvement
Add the label’s additional high-risk subgroup qualifiers and, for the under-2 population, include the instruction that divalproex sodium extended-release tablets should be used with extreme caution and as a sole agent (when used in this patient group).